Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Microbix Biosystems Inc. > New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(79)
•••
Comment by Mbxwatcheron Feb 14, 2024 4:18pm
126 Views
Post# 35880609

RE:RE:RE:RE:New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024

RE:RE:RE:RE:New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024That would seem to make sense.......
11 antigens
10 QAPS
 4.2 Kinlytic
.5  Royalties

25.7

Seems to be reasonable that is pretty close to the run rate they are at now.....

with Kinlytic coming down the pipe, and QAPS growing, I think its fair to say our prospects for growth are good.    One comment that was made is the their costs are scaled up for larger revenues, so EBITDA percentage should grow with sales....

Some VTM/Dxtm sales possible in the future based on Cameron's tone in the webinar.

.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities